Q2 2026 Holdings
Filed 2026-08-14 | 23 holdings | $642.6M | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| CG Oncology, Inc.(CGON) | COM | 156944100 | $168.4M | 2,369,574 | 26.2% |
| Alumis Inc.(ALMS) | COM | 022307102 | $119.5M | 4,247,670 | 18.6% |
| Seaport Therapeutics, Inc.(SPTX) | COM | 81221K108 | $38.7M | 1,779,521 | 6.0% |
| Denali Therapeutics Inc.(DNLI) | COM | 24823R105 | $35.9M | 1,396,771 | 5.6% |
| Celldex Therapeutics, Inc.(CLDX) | COM | 15117B202 | $32.7M | 879,713 | 5.1% |
| Agios Pharmaceuticals, Inc.(AGIO) | COM | 00847X104 | $29.1M | 785,000 | 4.5% |
| Corvus Pharmaceuticals, Inc.(CRVS) | COM | 221015100 | $27.4M | 1,831,233 | 4.3% |
| Parabilis Medicines, Inc.(PBLS) | COM | 698955101 | $27.3M | 999,044 | 4.3% |
| GH Research PLC(GHRS) | ORD | G3855L106 | $25.3M | 940,493 | 3.9% |
| Jade Biosciences, Inc.(JBIO) | COM | 008064206 | $19.7M | 886,667 | 3.1% |
| Hinge Health, Inc.(HNGE) | CL A | 433313103 | $18.3M | 220,400 | 2.8% |
| Kymera Therapeutics, Inc.(KYMR) | COM | 501575104 | $16.8M | 146,332 | 2.6% |
| AtaiBeckley Inc.(ATAI) | COM | 04650F101 | $14.5M | 2,750,000 | 2.3% |
| Verastem, Inc.(VSTM) | COM | 92337C203 | $12.0M | 3,146,631 | 1.9% |
| Beam Therapeutics Inc.(BEAM) | COM | 07373V105 | $11.3M | 330,000 | 1.8% |
| Minerva Neurosciences, Inc.(NERV) | COM | 603380205 | $11.0M | 1,985,584 | 1.7% |
| ArriVent BioPharma, Inc.(AVBP) | COM | 04272N102 | $10.5M | 301,341 | 1.6% |
| Aura Biosciences, Inc.(AURA) | COM | 05153U107 | $9.5M | 1,333,334 | 1.5% |
| Crinetics Pharmaceuticals, Inc.(CRNX) | COM | 22663K107 | $7.9M | 212,010 | 1.2% |
| Research Alliance Corp III | CL A | G75226103 | $3.2M | 300,000 | 0.5% |
| Zura Bio Ltd(ZURA) | CL A | G9TY5A101 | $2.7M | 450,000 | 0.4% |
| Kailera Therapeutics, Inc.(KLRA) | COM | 482931102 | $826.1K | 37,500 | 0.1% |
| Disc Medicine, Inc.(IRON) | COM | 254604101 | $70.9K | 970 | 0.0% |